Smart Cell Therapy: an industry perspective on macrophages as living drugs.

Abstract

Macrophage-based cell therapies represent a cutting-edge frontier in immunotherapy, offering distinct advantages over conventional approaches like CAR-T. This review explores the potential of macrophages to orchestrate both innate and adaptive immune responses, enhancing the body's ability to combat diseases locally and systemically. Dubbed a "Smart Cell Therapy," macrophages can initiate and coordinate complex immunological cascades, leveraging multiple immune system components while also performing effector functions. However, significant challenges persist in developing these therapies, including limited macrophage expansion capacity, inefficient genetic engineering, difficulties with large-scale production, and demonstrating late-stage clinical success. Despite these obstacles, ongoing research and clinical trials indicate that macrophage-based therapies hold immense potential to revolutionize treatment approaches across a spectrum of diseases, from cancer to regenerative medicine. With a focus on industry-led development, this review examines the current landscape of macrophage-based cellular therapies, discussing their promising potential and the substantial hurdles that must be overcome to realize their full therapeutic value.